Physician profile
Mohammad A Aslam
NPI 1992745137
$2,566.69
in general payments reported to CMS, 2019-2025
25 companies · $485 in 2025
The $485 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $267 · 2020: $305 · 2021: $393 · 2022: $548 · 2023: $298 · 2024: $271 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $989 · Education: $65.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $988.92 |
| Education | $65.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $579.83 | 2019-2025 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $223.14 | 2019-2025 | Filspari |
| Aurinia Pharma U.S., INC. | $214.22 | 2021-2025 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $210.25 | 2021-2023 | |
| Fresenius USA Marketing, INC. | $146.34 | 2019-2024 | Velphoro |
| Calliditas Therapeutics US INC. | $143.69 | 2022-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $130.49 | 2019-2024 | Jynarque |
| Amgen INC. | $118.25 | 2019-2025 | Tavneos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.33 | 2022-2025 | Jardiance |
| Akebia Therapeutics INC | $91.48 | 2019-2025 | Vafseo |
| Glaxosmithkline, LLC. | $89.10 | 2022-2025 | Benlysta, Arexvy, Shingrix |
| Alexion Pharmaceuticals, INC. | $83.54 | 2021-2023 | Ultomiris |
| Vifor Pharma, INC. | $80.39 | 2019-2023 | Korsuva, Veltassa |
| Mallinckrodt Hospital Products INC. | $67.69 | 2022 | |
| Ardelyx, INC. | $45.93 | 2024-2025 | Ibsrela |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $43.29 | 2021 | |
| Horizon Therapeutics Plc | $42.51 | 2022 | |
| Kyowa Kirin, INC. | $28.17 | 2022 | |
| Novo Nordisk INC | $25.60 | 2025 | Wegovy |
| Opko Pharmaceuticals, LLC | $21.90 | 2020 | |
| Janssen Pharmaceuticals, INC | $18.12 | 2020 | |
| Shire North American Group INC | $17.07 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.26 | 2020 | |
| Pfizer INC. | $11.99 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Aslam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.